Drug intelligence / Profile preview

mistletoe extract + pamidronate

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of mistletoe extract (derived from Viscum album) and pamidronate (a bisphosphonate). Mistletoe extract stimulates anti-cancer Vγ9Vδ2 T cells through butyrophilin BTN3A-dependent mechanisms, while pamidronate works by slowing bone breakdown, increasing bone density, and decreasing calcium release from bones into the blood. The combination may potentially offer synergistic effects through reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells.

Targets

γδ TCR (T-cell receptor)FDPS (Farnesyl pyrophosphate synthase)

Beyond the preview

Go deeper on mistletoe extract + pamidronate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mistletoe extract + pamidronate.

Explore the full profile